Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronically progressive interstitial lung disease that results in severe disability and death in the majority of cases. Although currently available medications, particularly corticosteroids and immunosuppressants, are prescribed with the hope of slowing progression of the disease, they are associated with significant side effects and morbidity. The primary reason why cluding asthma and chronic obstructive pulmonary disease (COPD), only a handful of studies have examined HRQL in IPF patients
. In fact, the impact of IPF on patients' HRQL is not fully understood, and the International Consensus Statement on IPF (1) (1, 10) . In addition, a recently developed serum marker for interstitial lung diseases, i.e. , has appeared on the clinical stage to evaluate interstitial lung diseases, including IPF (11, 12) . Since the previous investigators in this field, with one exception (8) , did not use some of these modalities, their studies may have failed to detect associations between clinical variables determined by these modalities and HRQL. Furthermore, to our knowledge, no study has measured longitudinal changes in HRQL in patients with IPF. The purposes of this study were (1) 
to compare the HRQL of IPF patients with that of the general population as a whole, (2) to test the a priori hypothesis that low HRQL scores correlate with more severe clinical parameters demonstrated by KL-6, pulmonary function tests, exercise tests, and HRCT, (3) to examine longitudinal changes in HRQL and (4) to test the a priori hypothesis that there is a correlation between decline in HRQL and clinical parameters.
Materials and Methods
Study subjects
Forty-six Japanese patients with IPF who were referred to or followed at the outpatient pulmonary clinic of the Nishi (16, 17 T a b l e 1 . B a s e l i n e Ch a r a c t e r i s t i c s o f P a t i e n t s ( n = 4 6 ) for both the baseline and repeated 6-min walk test. Informed consent was obtained from all participants, and the study protocol had the approval of the local ethics committee. Some data that we used had been collected as part of a prospective study of aerosolized N-acetylcysteine for IPF (19) .
Statistical Analysis
In 
Results
Cross-sectional Study
De v i a t i o n v a l u e s a g a i n s t t h e n a t i o n a l r e f e r e n c e v a l u e s o f t h e 8 h e a l t h c o mp o n e n t s o f t h e S F -3 6 .
Al l o f t h e me a n d e v i a t i o n v a l u e s we r e s i g n i f i c a n t l y b e l o w t h e n a t i o n a l r e f e r e n c e v a l u e s , i . e . 5 0 : P F , RP , RE a n d MH ( p < 0 . 0 0 1 ) , B P a n d S F ( p < 0 . 0 1 ) , GH a n d VT ( p < 0 . 0 0 0
) . Me a n ± S D i s s h o wn . P F , p h y s i c a l f u n c t i o n ; RP , r o l e -p h y s i c a l ; B P , b o d i l y p a i n ; GH, g e n e r a l h e a l t h ; VT , v i t a l i t y ; S F , s o c i a l f u n c t i o n i n g ; RE , r o l e -e mo t i o n a l ; MH, me n t a l h e a l t h .
T a b l e 2 . S p e a r ma n Co r r e l a t i o n Co e f f i c i e n t s ( ρ ) b e t we e n E a c h S F -3 6 Do ma i n a n d Cl i n i c a l P a r a me t e r s ( n = 4 6 )
(ρ=-0.48, p<0.01). Me a n S F -3 6 s c o r e s a t b a s e l i n e a n d a t f o l l o w u p . T h e r e wa s a s i g n i f i c a n t d e c l i n e i n  h e a l t h -r e l a t e d q u a l i t y o f l i f e i n 2 s u b s c a l e s : * P F ( p < 0 . 0 0 1 ) a n d * * B P ( p < 0 . 0 5 ) . S e e F i g u r e 1 f o r  a b b r e v i a t i o n T a b l e 3 . S p e a r ma n Co r r e l a t i o n Co e f f i c i e n t s ( ρ ) b e t we e n Wi t h i n -s u b j e c t Ch a n g e s i n S F -3 6 Do ma i n s a n d Ch a n g e s i n Cl i n i c a l P a r a me t e r s ( n = 3 2 )
Longitudinal study
T a b l e 4 . Co mp a r i s o n o f Wi t h i n -s u b j e c t Ch a n g e s ( me a n ± S E M) i n S F -3 6 Do ma i n s b e t we e n S u b j e c t s Wh o s e VC De c r e a s e d b y > = 1 0 % ( Wo r s e n i n g o f VC) a n d S u b j e c t s Wh o s e VC Di d No t De c r e a s e b y > = 1 0 % ( S t a b l e o r i mp r o v e d VC)
T a b l e 5 . Co mp a r i s o n o f Wi t h i n -s u b j e c t Ch a n g e s ( me a n ± S E M) i n S F -3 6 Do ma i n s b e t we e n S u b j e c t s Wh o s e DL c o De c r e a s e d b y > = 1 5 % ( Wo r s e n i n g o f DL c o ) a n d S u b j e c t s Wh o s e DL c o Di d No t De c r e a s e b y > = 1 5 % ( S t a b l e o r i mp r o v e d DL c o )
T a b l e 6 . Co mp a r i s o n o f Wi t h i n -s u b j e c t Ch a n g e s ( me a n ± S E M) i n S F -3 6 Do ma i n s b e t we e n S u b j e c t s Wh o s e L o we s t Ox y g e n S a t u r a t i o n d u r i n g 6 -mi n Wa l k i n g T e s t De c r e a s e d b y > = 4 P e r c e n t a g e P o i n t s ( Wo r s e n i n g o f Ox y g e n S a t u r a t i o n ) a n d S u b j e c t s wi t h o u t s u c h a De c r e a s e ( S t a b l e o r I mp r o v e d Ox y g e n S a t u r a t i o n )
0.05), ∆VT=-35.0±10.8 (p<0.01), and ∆SF=-37.5±20.4 (p< 0.05). (3, 20, 21) 
T a b l e 7 . Co mp a r i s o n o f Wi t h i n -s u b j e c t Ch a n g e s ( me a n ± S E M) i n S F -3 6 Do ma i n s b e t we e n S u b j e c t s Wh o De v e l o p e d t h e Ne e d f o r S u p p l e me n t a l Ox y g e n Du r i n g t h e F o l l o w Up a n d S u b j e c t s Wh o Di d No t
Discussion
. However, there is no disease-specific instrument for use in patients with IPF. Investigators have noted problems with some of the existing non-IPF respiratory disease-specific instruments when applied to patients with IPF. Developing an IPF-specific instrument that includes items most relevant to IPF patients would be ideal for evaluating the real HRQL in IPF (2).
There are a few cross-sectional studies (3, (5) (6) (7) (8) (23, 24) or asthma (25) , it also demonstrated sensitivity to changes in IPF in the present study.
Longitudinal studies also provide a platform for evaluating how IPF patients adapt to disease (2) . From (3, 5, 7, 8 
